CASE REPORTCilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour
References (4)
- et al.
Integrin αvβ3 antagonists promote tumour regression by inducing apoptosis od angiogenic blood vessels
Cell
(1994) - et al.
N-methylated RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists
J. Med. Chem.
(1999)
Cited by (86)
Tumor adhesion molecule targeting for breast cancer nanomedicine
2022, Targeted Nanomedicine for Breast Cancer TherapyIntegrins as attractive targets for cancer therapeutics
2021, Acta Pharmaceutica Sinica BCitation Excerpt :This αv inhibitor apparently acts by inhibiting the FAK/SRC/AKT pathway and triggering apoptosis in endothelial cells. Preclinical studies have revealed positive antiangiogenic effects in vitro136 and antitumor effects in vivo against melanoma, and also in head and neck cancer, breast cancer, and brain tumor137,138. Cilengitide has been used in trials for the treatment of sarcoma, glioma, lymphoma, leukemia, and lung cancer.
PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting αv integrin/FAK/Src signaling in oral squamous cell carcinoma cells
2019, Acta Pharmaceutica Sinica BCitation Excerpt :The overall pharmacological effect of RGD-containing peptidic agents is likely to be mediated via dual mechanisms, direct antitumor activity as well as interference with endothelial cell functions in cancer vasculature24. Given the highly vascularized nature of HNSCC, targeting neoangiogenesis could be a reasonable approach for depriving tumor of adequate nutrition and improving patient outcomes25. In such a context, our attention has been paid to a novel RGD-based PEP06 polypeptide, originating from the active fragment of natural inhibitor of angiogenesis endostatin.
Epigenetic regulation and targeting of ECM for cancer therapy
2022, American Journal of Physiology - Cell Physiology